UOC
GSK icon

UBS O'Connor’s GSK GSK Stock Holding History

UBS O'Connor’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,000
Closed -$2.9M – 493
2024
Q3 		$2.9M Buy
+71,000
New +$2.9M 0.07% 134
2023
Q4 		– Sell
-209,552
Closed -$7.6M – 551
2023
Q3 		$7.6M Buy
209,552
+85,000
+68% +$3.02M 0.14% 80
2023
Q2 		$4.44M Buy
124,552
+6,136
+5% +$220K 0.09% 137
2023
Q1 		$4.21M Buy
118,416
+5,639
+5% +$197K 0.1% 157
2022
Q4 		$3.96M Sell
112,777
-52,299
-32% -$1.74M 0.07% 245
2022
Q3 		$4.86M Buy
+165,076
New +$6.26M 0.06% 223
2022
Q2 		– Sell
-33,991
Closed -$1.85M – 980
2022
Q1 		$1.85M Buy
+33,991
New +$1.85M 0.02% 608

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS O'Connor's GSK Position: Q4 2024 in Review

UBS O'Connor sold out of GSK (GSK) in Q4 2024, closing a stake of 71,000 shares — an estimated $2.9M sold.

UBS O'Connor first reported a position in GSK in Q1 2022 and held it in 7 quarters. The position peaked at $7.6M in Q3 2023. 850 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • UBS O'Connor reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 71,000 GSK shares in Q4 2024, an estimated $2.9M.
  • UBS O'Connor first reported a position in GSK in Q1 2022 and held it in 7 quarters.
  • UBS O'Connor's GSK position peaked at $7.6M in Q3 2023.
  • 850 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.